Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Click Conjugation of Cloaked Peptide Ligands to Microbubbles.

Slagle CJ, Thamm DH, Randall EK, Borden MA.

Bioconjug Chem. 2018 Apr 11. doi: 10.1021/acs.bioconjchem.8b00084. [Epub ahead of print]

PMID:
29614859
2.

Comparative oncology approach to drug repurposing in osteosarcoma.

Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M, Bruns T, Thamm DH, Weir SJ, Neville KA, Iwakuma T, Fulbright JM.

PLoS One. 2018 Mar 26;13(3):e0194224. doi: 10.1371/journal.pone.0194224. eCollection 2018.

3.

Pilot study utilizing Fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography for glycolytic phenotyping of canine mast cell tumors.

Griffin LR, Thamm DH, Selmic LE, Ehrhart EJ, Randall E.

Vet Radiol Ultrasound. 2018 Mar 23. doi: 10.1111/vru.12612. [Epub ahead of print]

PMID:
29570234
4.

Editorial.

Thamm DH.

Vet Comp Oncol. 2018 Mar;16(1):1. doi: 10.1111/vco.12392. No abstract available.

PMID:
29465825
5.

Canine sarcomas as a surrogate for the human disease.

Gustafson DL, Duval DL, Regan DP, Thamm DH.

Pharmacol Ther. 2018 Mar 9. pii: S0163-7258(18)30019-6. doi: 10.1016/j.pharmthera.2018.01.012. [Epub ahead of print] Review.

PMID:
29378221
6.

Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model.

Zhang H, Diao H, Jia L, Yuan Y, Thamm DH, Wang H, Jin Y, Pei S, Zhou B, Yu F, Zhao L, Cheng N, Du H, Huang Y, Zhang D, Lin D.

PLoS One. 2017 Dec 5;12(12):e0188960. doi: 10.1371/journal.pone.0188960. eCollection 2017.

7.

c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.

Weishaar KM, Ehrhart EJ, Avery AC, Charles JB, Elmslie RE, Vail DM, London CA, Clifford CA, Eickhoff JC, Thamm DH.

J Vet Intern Med. 2018 Jan;32(1):394-405. doi: 10.1111/jvim.14889. Epub 2017 Nov 30.

8.

Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses.

Saba CF, Vickery KR, Clifford CA, Burgess KE, Phillips B, Vail DM, Wright ZM, Morges MA, Fan TM, Thamm DH.

Vet Comp Oncol. 2018 Mar;16(1):E76-E82. doi: 10.1111/vco.12337. Epub 2017 Sep 11.

PMID:
28891260
9.

Characterization of a low expression haplotype in canine glutathione S-transferase (GSTT1) and its prevalence in golden retrievers.

Craft S, Ekena J, Mayer B, Thamm DH, Saba C, Chun R, Trepanier LA.

Vet Comp Oncol. 2018 Mar;16(1):E61-E67. doi: 10.1111/vco.12333. Epub 2017 Aug 25.

PMID:
28840668
10.

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

Laver T, London CA, Vail DM, Biller BJ, Coy J, Thamm DH.

Vet Comp Oncol. 2018 Mar;16(1):E23-E29. doi: 10.1111/vco.12328. Epub 2017 Jun 15.

PMID:
28621057
11.

Canine Cutaneous Plasmacytosis: 21 Cases (2005-2015).

Boostrom BO, Moore AS, DeRegis CJ, Robat C, Freeman K, Thamm DH.

J Vet Intern Med. 2017 Jul;31(4):1074-1080. doi: 10.1111/jvim.14729. Epub 2017 May 17.

12.

Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol.

Wilson-Robles H, Budke CM, Miller T, Dervisis N, Novosad A, Wright Z, Thamm DH, Vickery K, Burgess K, Childress M, Lori J, Saba C, Rau S, Silver M, Post G, Reeds K, Gillings S, Schleis S, Stein T, Brugmann B, DeRegis C, Smrkovski O, Lawrence J, Laver T.

Vet Comp Oncol. 2017 Dec;15(4):1564-1571. doi: 10.1111/vco.12302. Epub 2017 Apr 17.

PMID:
28419683
13.

Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.

Thamm DH, Vail DM, Post GS, Fan TM, Phillips BS, Axiak-Bechtel S, Elmslie RS, Klein MK, Ruslander DA.

J Vet Intern Med. 2017 May;31(3):872-878. doi: 10.1111/jvim.14700. Epub 2017 Apr 3.

14.

Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.

Marvel SJ, Séguin B, Dailey DD, Thamm DH.

Vet Comp Oncol. 2017 Dec;15(4):1417-1427. doi: 10.1111/vco.12286. Epub 2017 Feb 20.

PMID:
28217972
15.

Expression of Phosphorylated KIT in Canine Mast Cell Tumor.

Halsey CHC, Thamm DH, Weishaar KM, Burton JH, Charles JB, Gustafson DL, Avery AC, Ehrhart EJ.

Vet Pathol. 2017 May;54(3):387-394. doi: 10.1177/0300985816688943. Epub 2017 Jan 27.

PMID:
28129097
16.

Epithelial Cell Adhesion Molecule Expression in Canine Tumours.

Thamm DH, Hayes DF, Meuten T, Laver T, Thomas DG.

J Comp Pathol. 2016 Nov;155(4):299-304. doi: 10.1016/j.jcpa.2016.07.010. Epub 2016 Aug 24.

PMID:
27567927
17.

Relative biological effectiveness in canine osteosarcoma cells irradiated with accelerated charged particles.

Maeda J, Cartwright IM, Haskins JS, Fujii Y, Fujisawa H, Hirakawa H, Uesaka M, Kitamura H, Fujimori A, Thamm DH, Kato TA.

Oncol Lett. 2016 Aug;12(2):1597-1601. Epub 2016 Jun 30.

18.

Intrinsic Radiosensitivity and Cellular Characterization of 27 Canine Cancer Cell Lines.

Maeda J, Froning CE, Brents CA, Rose BJ, Thamm DH, Kato TA.

PLoS One. 2016 Jun 3;11(6):e0156689. doi: 10.1371/journal.pone.0156689. eCollection 2016.

19.

The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.

Fowles JS, Dailey DD, Gustafson DL, Thamm DH, Duval DL.

Vet Comp Oncol. 2017 Jun;15(2):481-492. doi: 10.1111/vco.12192. Epub 2016 May 19.

20.

Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C.

Sci Transl Med. 2016 Feb 3;8(324):324ps5. doi: 10.1126/scitranslmed.aaf0746. Review. No abstract available.

PMID:
26843188
21.

Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.

Curran K, Thamm DH.

Vet Comp Oncol. 2016 Aug;14 Suppl 1:147-55. doi: 10.1111/vco.12163. Epub 2015 Aug 17.

PMID:
26279153
22.

What Is Your Diagnosis? Renal adenocarcinoma.

Duffy DJ, Kendall AR, Thamm DH, Marolf AJ.

J Am Vet Med Assoc. 2015 Aug 1;247(3):247-9. doi: 10.2460/javma.247.3.247. No abstract available.

PMID:
26176722
23.

Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.

Burton JH, Venable RO, Vail DM, Williams LE, Clifford CA, Axiak-Bechtel SM, Avery AC, Thamm DH.

J Vet Intern Med. 2015 Jul-Aug;29(4):1098-104. doi: 10.1111/jvim.13573. Epub 2015 Jun 25.

24.

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.

Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD.

BMC Vet Res. 2015 Jun 11;11:131. doi: 10.1186/s12917-015-0446-1.

25.

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.

London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G.

PLoS One. 2015 Apr 29;10(4):e0124889. doi: 10.1371/journal.pone.0124889. eCollection 2015.

27.

Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.

Pilon JL, Clausen DJ, Hansen RJ, Lunghofer PJ, Charles B, Rose BJ, Thamm DH, Gustafson DL, Bradner JE, Williams RM.

Cancer Chemother Pharmacol. 2015 Apr;75(4):671-82. doi: 10.1007/s00280-015-2675-1. Epub 2015 Jan 24.

28.

Veterinary oncology clinical trials: design and implementation.

Thamm DH, Vail DM.

Vet J. 2015 Aug;205(2):226-32. doi: 10.1016/j.tvjl.2014.12.013. Epub 2014 Dec 19. Review.

PMID:
25582798
29.

Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.

Morges MA, Burton JH, Saba CF, Vail DM, Burgess KE, Thamm DH.

J Vet Intern Med. 2014 Sep-Oct;28(5):1569-74. doi: 10.1111/jvim.12429.

30.

The immunosignature of canine lymphoma: characterization and diagnostic application.

Johnston SA, Thamm DH, Legutki JB.

BMC Cancer. 2014 Sep 8;14:657. doi: 10.1186/1471-2407-14-657.

31.

Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis.

Weishaar KM, Thamm DH, Worley DR, Kamstock DA.

J Comp Pathol. 2014 Nov;151(4):329-38. doi: 10.1016/j.jcpa.2014.07.004. Epub 2014 Aug 27.

PMID:
25172053
32.

Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog.

Weishaar KM, Edmondson EF, Thamm DH, Olver CS.

Vet Clin Pathol. 2014 Sep;43(3):447-52. doi: 10.1111/vcp.12180. Epub 2014 Jul 30.

PMID:
25132008
33.

Serum 25-hydroxyvitamin D concentrations in dogs - correlation with health and cancer risk.

Selting KA, Sharp CR, Ringold R, Thamm DH, Backus R.

Vet Comp Oncol. 2016 Sep;14(3):295-305. doi: 10.1111/vco.12101. Epub 2014 Jul 8.

PMID:
25041357
34.

Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.

Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH.

Autophagy. 2014 Aug;10(8):1415-25. doi: 10.4161/auto.29165. Epub 2014 May 20.

35.

Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.

Shoeneman JK, Ehrhart EJ 3rd, Charles JB, Thamm DH.

Vet Comp Oncol. 2016 Jun;14(2):e45-57. doi: 10.1111/vco.12104. Epub 2014 Jun 13.

PMID:
24923332
36.

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.

Halsey CH, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH.

BMC Vet Res. 2014 May 6;10:105. doi: 10.1186/1746-6148-10-105.

37.

Autophagy and cancer therapy.

Thorburn A, Thamm DH, Gustafson DL.

Mol Pharmacol. 2014 Jun;85(6):830-8. doi: 10.1124/mol.114.091850. Epub 2014 Feb 26. Review.

38.

Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Selmic LE, Burton JH, Thamm DH, Withrow SJ, Lana SE.

J Vet Intern Med. 2014 Mar-Apr;28(2):554-63. doi: 10.1111/jvim.12313. Epub 2014 Feb 10.

39.

GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.

Thamm DH, Vail DM, Kurzman ID, Babusis D, Ray AS, Sousa-Powers N, Tumas DB.

BMC Vet Res. 2014 Jan 25;10:30. doi: 10.1186/1746-6148-10-30.

40.

Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma.

Kaye ME, Thamm DH, Weishaar K, Lawrence JA.

Vet Comp Oncol. 2015 Dec;13(4):443-51. doi: 10.1111/vco.12065. Epub 2013 Aug 25.

PMID:
23981116
41.

DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study.

Thamm DH, Grunerud KK, Rose BJ, Vail DM, Bailey SM.

PLoS One. 2013 Jul 23;8(7):e69192. doi: 10.1371/journal.pone.0069192. Print 2013.

42.

HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.

Dailey DD, Anfinsen KP, Pfaff LE, Ehrhart EJ, Charles JB, Bønsdorff TB, Thamm DH, Powers BE, Jonasdottir TJ, Duval DL.

BMC Vet Res. 2013 Jul 1;9:130. doi: 10.1186/1746-6148-9-130.

43.

Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines.

Lawrence JA, Huelsmeyer MK, Thamm DH, Tumas DB, Birkus G, Kurzman I, Vail DM.

Vet Comp Oncol. 2015 Sep;13(3):246-54. doi: 10.1111/vco.12038. Epub 2013 May 15.

44.

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.

Nguyen SM, Thamm DH, Vail DM, London CA.

Vet Comp Oncol. 2015 Sep;13(3):176-83. doi: 10.1111/vco.12032. Epub 2013 Mar 28.

PMID:
23534501
45.

Immunohistochemical characterization of feline oral squamous cell carcinoma.

Yoshikawa H, Ehrhart EJ, Charles JB, Thamm DH, Larue SM.

Am J Vet Res. 2012 Nov;73(11):1801-6. doi: 10.2460/ajvr.73.11.1801.

PMID:
23106467
46.

Genomic instability and telomere fusion of canine osteosarcoma cells.

Maeda J, Yurkon CR, Fujisawa H, Kaneko M, Genet SC, Roybal EJ, Rota GW, Saffer ER, Rose BJ, Hanneman WH, Thamm DH, Kato TA.

PLoS One. 2012;7(8):e43355. doi: 10.1371/journal.pone.0043355. Epub 2012 Aug 16.

47.

Tyrosine kinase inhibitor special issue.

Thamm DH.

Vet Comp Oncol. 2012 Sep;10(3):161-2. doi: 10.1111/j.1476-5829.2012.00339.x. No abstract available.

PMID:
22882484
48.

An asymmetric synthesis of 1,2,4-trioxane anticancer agents via desymmetrization of peroxyquinols through a Brønsted acid catalysis cascade.

Rubush DM, Morges MA, Rose BJ, Thamm DH, Rovis T.

J Am Chem Soc. 2012 Aug 22;134(33):13554-7. doi: 10.1021/ja3052427. Epub 2012 Aug 7.

49.

Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.

Wittenburg LA, Thamm DH, Gustafson DL.

Vet Comp Oncol. 2014 Jun;12(2):114-9. doi: 10.1111/j.1476-5829.2012.00340.x. Epub 2012 Jul 3.

50.

Diagnostic accuracy of pre-treatment biopsy for grading soft tissue sarcomas in dogs.

Perry JA, Culp WT, Dailey DD, Eickhoff JC, Kamstock DA, Thamm DH.

Vet Comp Oncol. 2014 Jun;12(2):106-13. doi: 10.1111/j.1476-5829.2012.00333.x. Epub 2012 May 22.

PMID:
22617002

Supplemental Content

Loading ...
Support Center